IQVIA (NYSE:IQV) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS

IQVIA (NYSE:IQV) released its earnings results on Tuesday. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12, FiscalAI reports. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the company earned $2.81 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA updated its FY 2026 guidance to 12.800-13.000 EPS.

IQVIA Trading Up 2.3%

Shares of IQV stock opened at $212.76 on Tuesday. The stock has a market cap of $35.51 billion, a price-to-earnings ratio of 26.36, a P/E/G ratio of 1.87 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a 52-week low of $154.50 and a 52-week high of $247.04. The firm has a fifty day moving average of $189.02 and a 200-day moving average of $186.85.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Gilpin Wealth Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $28,000. Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA in the 3rd quarter worth about $30,000. Johnson Financial Group Inc. acquired a new stake in shares of IQVIA during the 3rd quarter worth about $52,000. Finally, DV Equities LLC bought a new position in IQVIA during the 4th quarter valued at about $53,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Mizuho lifted their target price on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Robert W. Baird boosted their price target on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.